These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26464711)

  • 1. Hypomethylation of DNA-binding inhibitor 4 serves as a potential biomarker in distinguishing acquired tamoxifen-refractory breast cancer.
    Zhang Y; Zhang B; Fang J; Cao X
    Int J Clin Exp Pathol; 2015; 8(8):9500-5. PubMed ID: 26464711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DOK7 CpG hypermethylation in blood leukocytes as an epigenetic biomarker for acquired tamoxifen resistant in breast cancer.
    Gowdini E; Aleyasin SA; Ramezani N; Nafisi N; Tutuni M
    J Hum Genet; 2023 Jan; 68(1):33-38. PubMed ID: 36372800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Promoter methylation of ID4. A marker for recurrence-free survival in human breast cancer].
    Noetzel E; Veeck J; Horn F; Hartmann A; Knüchel R; Dahl E
    Pathologe; 2008 Nov; 29 Suppl 2():319-27. PubMed ID: 18807039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the epigenetic profile of ID4 in breast cancer: bioinformatic insights into methylation patterns and chromatin accessibility dynamics.
    Nasif D; Laurito S; Real S; Branham MT
    Breast Cancer Res Treat; 2024 Aug; 207(1):91-101. PubMed ID: 38702584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
    Maier S; Nimmrich I; Koenig T; Eppenberger-Castori S; Bohlmann I; Paradiso A; Spyratos F; Thomssen C; Mueller V; Nährig J; Schittulli F; Kates R; Lesche R; Schwope I; Kluth A; Marx A; Martens JW; Foekens JA; Schmitt M; Harbeck N;
    Eur J Cancer; 2007 Jul; 43(11):1679-86. PubMed ID: 17601725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients.
    Cerne JZ; Zong L; Jelinek J; Hilsenbeck SG; Wang T; Oesterreich S; McGuire SE
    Breast Cancer Res Treat; 2012 Aug; 135(1):135-43. PubMed ID: 22706629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer.
    Noetzel E; Veeck J; Niederacher D; Galm O; Horn F; Hartmann A; Knüchel R; Dahl E
    BMC Cancer; 2008 May; 8():154. PubMed ID: 18513385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese.
    Kiyotani K; Mushiroda T; Tsunoda T; Morizono T; Hosono N; Kubo M; Tanigawara Y; Imamura CK; Flockhart DA; Aki F; Hirata K; Takatsuka Y; Okazaki M; Ohsumi S; Yamakawa T; Sasa M; Nakamura Y; Zembutsu H
    Hum Mol Genet; 2012 Apr; 21(7):1665-72. PubMed ID: 22180457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy.
    Foekens JA; Romain S; Look MP; Martin PM; Klijn JG
    Cancer Res; 2001 Feb; 61(4):1421-5. PubMed ID: 11245445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer.
    Martens JW; Nimmrich I; Koenig T; Look MP; Harbeck N; Model F; Kluth A; Bolt-de Vries J; Sieuwerts AM; Portengen H; Meijer-Van Gelder ME; Piepenbrock C; Olek A; Höfler H; Kiechle M; Klijn JG; Schmitt M; Maier S; Foekens JA
    Cancer Res; 2005 May; 65(10):4101-17. PubMed ID: 15899800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer.
    Umetani N; Mori T; Koyanagi K; Shinozaki M; Kim J; Giuliano AE; Hoon DS
    Oncogene; 2005 Jul; 24(29):4721-7. PubMed ID: 15897910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
    Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
    Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinico-pathology and prognosis of endometrial cancer in patients previously treated for breast cancer, with or without tamoxifen: a comparative study in 363 patients.
    Ngô C; Brugier C; Plancher C; de la Rochefordière A; Alran S; Féron JG; Malhaire C; Scholl S; Sastre X; Rouzier R; Fourchotte V;
    Eur J Surg Oncol; 2014 Oct; 40(10):1237-44. PubMed ID: 25086993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
    Filipits M; Rudas M; Heinzl H; Jakesz R; Kubista E; Lax S; Schippinger W; Dietze O; Greil R; Stiglbauer W; Kwasny W; Nader A; Stierer M; Gnant MF;
    Clin Cancer Res; 2009 Sep; 15(18):5888-94. PubMed ID: 19723645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.
    Meattini I; Livi L; Saieva C; Franceschini D; Scotti V; Mangoni M; Loi M; Di Brina L; Zei G; Bonomo P; Greto D; Gelain E; Nori J; Sanchez LJ; Orzalesi L; Bianchi S; Biti G
    Clin Breast Cancer; 2013 Aug; 13(4):247-53. PubMed ID: 23684167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
    Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
    J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
    Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
    Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.